Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial.

MLA

Friedman-Klabanoff, DeAnna J., et al. “Safety and Immunogenicity of AGS-v PLUS, a Mosquito Saliva Peptide Vaccine against Arboviral Diseases: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial.” EBioMedicine, vol. 86, Dec. 2022, p. 104375. EBSCOhost, https://doi.org/10.1016/j.ebiom.2022.104375.

APA

Friedman-Klabanoff, D. J., Birkhold, M., Short, M. T., Wilson, T. R., Meneses, C. R., Lacsina, J. R., Oliveira, F., Kamhawi, S., Valenzuela, J. G., Hunsberger, S., Mateja, A., Stoloff, G., Pleguezuelos, O., Memoli, M. J., & Laurens, M. B. (2022). Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial. EBioMedicine, 86, 104375. https://doi.org/10.1016/j.ebiom.2022.104375

Chicago

Friedman-Klabanoff, DeAnna J, Megan Birkhold, Mara T Short, Timothy R Wilson, Claudio R Meneses, Joshua R Lacsina, Fabiano Oliveira, et al. 2022. “Safety and Immunogenicity of AGS-v PLUS, a Mosquito Saliva Peptide Vaccine against Arboviral Diseases: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial.” EBioMedicine 86 (December): 104375. doi:10.1016/j.ebiom.2022.104375.